DURHAM, the United States, and LIEGE, BELGIUM - September 23rd, 2010 - OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA), a leading molecular diagnostics company, announced today that it has entered into an agreement with GlaxoSmithKline Biologicals S.A. (GSK) for the potential use of one of its DNA methylation specific PCR biomarkers in GSKs immunotherapy development program. Additional financial details were not disclosed.

OncoMethylome's biomarker is stable, highly accurate, and, unlike many other biomarkers, allows for the analysis of non-invasive tissue samples.

"We are very pleased to enter into this agreement with GSK. This project was initiated in 2007 and is a prime example of how we can bring our considerable regional strengths to bear on global healthcare issues," said Jan Groen, Ph.D., Chief Executive Officer of OncoMethylome. "Furthermore, this agreement marks an important step for our company in the use of our biomarker with certain immunotherapeutics in development by GSK, and underpins our strategy of leveraging our methylation specific PCR platform in the rapidly emerging field of companion diagnostics and personalized medicine."

About OncoMethylome Sciences
OncoMethylome Sciences is a leading molecular diagnostics company that commercializes and develops tests to assist physicians in detecting and treating cancer. The company's tests are based on proprietary gene methylation technology and are designed to help the physician accurately detect early stages of cancer, predict a patient's response to drug therapy, and predict the likelihood of cancer recurrence. OncoMethylome Sciences collaborates with leading cancer research centers, such as Johns Hopkins, in Baltimore, MD, and has a number of commercial and collaborative partnerships with LabCorp, Schering-Plough, GlaxoSmithKline Biologicals, Roche, Merck Serono and Qiagen.